HighTower Advisors
PVLA

HighTower Advisors’s Palvella Therapeutics PVLA Stock Holding History

HighTower Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-188
Closed -$34K – 2203
2015
Q4 		$34K Buy
+188
New +$31.6K ﹤0.01% 1917

Other funds holding PVLA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's PVLA Position: Q1 2016 in Review

HighTower Advisors sold out of Palvella Therapeutics (PVLA) in Q1 2016, closing a stake of 188 shares — an estimated $34K sold.

HighTower Advisors first reported a position in PVLA in Q4 2015 and held it in 1 quarter. The position peaked at $34K in Q4 2015. 17 funds tracked by Wall St. Rank hold PVLA as of Q1 2016.

  • HighTower Advisors reported no remaining Palvella Therapeutics position as of Q1 2016 after selling out during the quarter.
  • HighTower Advisors sold 188 Palvella Therapeutics shares in Q1 2016, an estimated $34K.
  • HighTower Advisors first reported a position in Palvella Therapeutics in Q4 2015 and held it in 1 quarter.
  • HighTower Advisors's Palvella Therapeutics position peaked at $34K in Q4 2015.
  • 17 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2016.

Based on HighTower Advisors's 13F filing for Q1 2016, filed 16 May 2016.